Searched for
CONCORD BIOTECH SHARES
Two Trades for Today: A maker of forged components for a 7.7% gain, a mid-cap pharma stock for a 6% upmoveOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended higher on Tuesday, supported by easing geopolitical tensions and softer crude prices. A sharp drop in India VIX boost...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian benchmark indices ended higher after a volatile session, with late buying in heavyweight IT stocks lifting sentiment. Sensex gained ...
- Stocks in news: BPCL, Adani Wilmar, Vodafone Idea, Cyient, Concord BiotechIn today's trade, shares of BPCL, Adani Wilmar, Vodafone Idea, Cyient, Concord Biotech among others will be in focus due to various news de...
- Concord Biotech shares tumble 16% after weak Q3 earningsConcord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 crore, despit...
- Concord Biotech stock slips over 5% after Rs 519 crore worth of shares change handsShares of Concord Biotech fell 5.3% on BSE due to a large block deal where Ontario Inc. sold a 3.4% stake at a discount, impacting stock pe...
- Concord Biotech's niche strengths seen buoying earnings: AnalystsShares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain sinc...
- Concord Biotech shares list at a healthy premium. What should investors do?Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech shares list at 21% premium over IPO priceConcord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...
- Concord Biotech IPO share allotment likely today. Here's how you can check statusOn the allotment date, investors get to know about the number of shares allotted to them as against the bids made. They can check the allot...
- SBFC Finance vs Concord Biotech: Which IPO should you pick?The issue of SBFC Finance comprises fresh equity issue of Rs 600 crore and an offer for sale (OFS) of Rs 425 crore, while Concord Biotech i...
- Concord Biotech IPO to open on August 4. Here are 10 things to know about the offerThe initial public offering (IPO) of Concord Biotech will open for subscription on August 4. The issue closes on August 8. The company's sh...
- Concord Bio's Rs 1,551-crore IPO to open on Aug 4The issue, which will close on August 8, is entirely an offer-for-sale, where the existing shareholder Helix Investments Holdings will sell...
- Jhunjhunwala-backed Concord Biotech sets IPO price band at Rs 705-741According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investmen...
- Lupin, Concord Biotech get USFDA nod for generic immunosuppressant capsulesIn alliance with Concord Biotech, the company has received approval from the United States Food and Drug Administration (USFDA) to market T...
- Quadria Cap concludes Rs 475.31 crore investment in ConcordPrivate equity firm Quadria Capital has concluded a Rs 475.31 crore investment in biopharmaceutical active ingredient manufacturer Concord ...
- Rakesh Jhunjhunwala to give up Concord Biotech stake, eyes Rs 500 crJhunjhunwala is looking to make a quick buck by exiting one of his large investments in the pharma space taking advantage of attractive val...
Load More
